Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary biliary cholangitis. The company also engages in the development of TH023 to treat autoimmune indications; and HS1940, a bispecific biologic against PD-1 and vascular endothelial growth receptor antibody that targets both receptors. It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc.